|
Market Closed -
OTC Markets
15:58:17 2023-09-07 EDT
|
5-day change | 1st Jan Change | ||
| 120,000.00 USD | -.--% |
|
-20.00% | -20.00% |
| 22-01-20 | Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index | CI |
| 22-01-20 | Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index | CI |
| Market Cap | 51.95M 44.7M 41.94M 38.38M 71.62M 4.91B 72.19M 496M 193M 2.51B 195M 191M 8.08B | P/E 2019 * |
-
| P/E 2020 | - |
|---|---|---|---|---|---|
| Enterprise Value | -99.99M -86.03M -80.73M -73.87M -138M -9.45B -139M -955M -372M -4.83B -375M -367M -15.56B | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
96% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 week | -20.00% | ||
| Current month | -20.00% | ||
| 1 month | -20.00% | ||
| 3 months | -20.00% | ||
| 6 months | -20.00% | ||
| Current year | -20.00% |
| 3 years | 3,000 |  | 399,160 |
| 5 years | 3,000 | | 399,160 |
| 10 years | 3,000 | | 3,719,992 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Hearne
DFI | Director of Finance/CFO | 63 | 2018-11-18 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/1/21 | EcoR1 Capital, LLC
| Buy | Company | 6,073,551 | 15.7794% | |
| 11/22/21 | Tavistock Life Sciences Co. (Investment Management)
| Sell | Company | 400,000 | 1.0390% | |
| 11/17/21 | Tavistock Life Sciences Co. (Investment Management)
| Sell | Company | 1,000,000 | 2.5974% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -20.00% | -20.00% | -.--% | 53.25M | |
| -0.04% | -1.40% | +57.16% | +108.15% | 1,034B | |
| +1.17% | +4.76% | +56.42% | +73.50% | 671B | |
| -0.58% | +0.80% | +22.82% | +75.58% | 460B | |
| +0.27% | -0.39% | +29.60% | +38.68% | 353B | |
| -0.73% | +5.45% | +25.56% | +46.56% | 309B | |
| +0.47% | +1.82% | 0.00% | +14.01% | 255B | |
| +0.29% | +1.63% | +56.46% | +73.00% | 240B | |
| +0.02% | +2.32% | -16.13% | -53.87% | 207B | |
| +1.08% | +1.59% | +33.83% | +97.29% | 188B | |
| Average | +0.14% | +1.14% | +24.57% | +47.29% | 371.68B | |
| Weighted average by Cap. | +0.05% | +1.04% | +38.30% | +67.82% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -112M -96.21M -90.29M -82.61M -154M -10.57B -155M -1.07B -416M -5.4B -420M -411M -17.4B | -126M -109M -102M -93.34M -174M -11.94B -176M -1.21B -470M -6.1B -474M -464M -19.66B |
| Net Debt | -178M -153M -144M -132M -246M -16.86B -248M -1.7B -664M -8.62B -670M -655M -27.76B | -152M -131M -123M -112M -209M -14.36B -211M -1.45B -565M -7.34B -571M -558M -23.64B |
Employees
145
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ODTC Stock
Select your edition
All financial news and data tailored to specific country editions
